OCT-Based Evaluation of Vitreous Haze in the First-Line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial
Year: 2026
Type: article
Abstract: Purpose: To evaluate OCT vitreous signal intensity (OCT-VI) as a biomarker of vitreous haze (VH) in a longitudinal, prospective, and standardized manner in the First-Line Antimetabolites as Steroid-Sparing Treatment (FAST) Uveitis Trial. Design: Secondary analysis of a block-randomized, observer-masked, multicenter clinical trial. Subjects: Two hundred sixty-seven eyes from 147 patients with uveitis enrolled in the FAST Trial were evaluated in this analysis at baseline (BL), month 6 (M6), and month 12 (M12). Methods: For each patient, Heidelberg Spectralis OCT volume scans (Heidelberg Engineering) were imported into the Doheny Reading Center 3D-OCTOR software and underwent a semi-automated segmentation. For each OCT volume, 5 B-scans were used to calculate the OCT-VI as a ratio of the vitreous space to the entire image. Main Outcome Measures: OCT vitreous signal intensity at BL, M6, and M12 visits and the association with the National Eye Institute VH scale, anterior chamber (AC) cell grade, posterior synechiae (PS), lens status, visual acuity (VA), and central macular thickness (CMT). Results: > 0.05) of OCT-VI with PS or CMT. Conclusions: In the FAST Uveitis Trial, OCT-VI was significantly correlated with the VH clinical grades and demonstrated significant longitudinal changes. OCT vitreous signal intensity may serve as a potential objective biomarker of VH. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Source: Ophthalmology Science
Authors: Mai Alhelaly, Ceren Soylu, Deniz Oncel, Giulia Corradetti, Keren Chen, Nicholas J. Jackson, Sivakumar R. Rathinam, John A. Gonzales, Radhika Thundikandy, Anuradha Vadakke Kanakath, S. Bala Murugan, Rajesh Vedhanayaki, Lyndell L. Lim, Eric B. Suhler, Hassan A. Al-Dhibi, Thuy Doan, Srinivas R. Sadda, Brian Madow, Alison B. Coyne, Nisha R. Acharya, Edmund Tsui
Institutions: University of California, Los Angeles, Tanta University, Doheny Eye Institute, Aravind Eye Hospital, University of California, San Francisco, The Royal Victorian Eye & Ear Hospital, Centre for Eye Research Australia, Oregon Health & Science University, King Khaled Eye Specialist Hospital, University at Buffalo, State University of New York
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,500
Funders: Amgen, Gilead Sciences, Biogen, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Regeneron Pharmaceuticals, Kowa Company, Apellis Pharmaceuticals, Bayer HealthCare, Carl Zeiss Meditec AG, Astellas Pharma, Heidelberg Engineering, National Institutes of Health, Genentech, Samsung, Allergan, Novartis Pharma, National Eye Institute, Janssen Pharmaceuticals
OpenAlex ID: W7128051933